Furthermore, the recurrent cancers with the frequent genetic amplification of SLC6A3, such as pancreatic cancer, and CRPC, indicate the potential cross-fertilization between two research fields when carrying out the re-drug positioning analysis; the properties of Benz in the treatment of Parkinson’s disease cast significant light on its potential mechanisms in cancer therapy. This evidence concerns the gene SLC6A3 and Parkinson disease.